Information Provided By: 
Fly News Breaks for March 5, 2020
IONS
Mar 5, 2020 | 15:29 EDT
Wells Fargo analyst Jim Birchenough believes the weakness this afternoon in shares of Ionis Pharmaceuticals represents a misreading of the trial suspension posted on ClinicalTrials.gov. The study that is temporarily suspended is a small 20 patient PK study which was suspended due to two serious adverse events related to intrathecal catheter infection, Birchenough tells investors in a research note. The analyst would be a buyer of Ionis on today's weakness.
News For IONS From the Last 2 Days
There are no results for your query IONS
